Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Stanford Health Care

Association between CYP3A4, CYP3A5 and ABCB1 genotype and tacrolimus treatment outcomes among allogeneic HSCT patients

Association between <i>CYP3A4</i>, <i>CYP3A5</i> and <i>ABCB1</i> genotype and tacrolimus treatment outcomes among allogeneic HSCT patients PHARMACOGENOMICS Ho, T. T., Perkins, J. B., Gonzalez, R., Hicks, J., Martinez, R., Duranceau, K., North, B., Kim, J., Teer, J. K., Yao, J., Yoder, S. J., Nishihori, T., Bejanyan, N., Pidala, J., Elmariah, H. 2024; 25 (1): 29-40

Abstract

Aim: Successful treatment with tacrolimus to prevent graft versus host disease (GVHD) and minimize tacrolimus-related toxicities among allogeneic hematopoietic cell transplantation (alloHCT) recipients is contingent upon quickly achieving and maintaining concentrations within a narrow therapeutic range. The primary objective was to investigate associations between CYP3A4, CYP3A5 or ABCB1 genotype and the proportion of patients that attained an initial tacrolimus goal concentration following initiation of intravenous (iv.) and conversion to oral administration. Materials & methods: We retrospectively evaluated 86 patients who underwent HLA-matched (8/8) related donor alloHCT and were prescribed a tacrolimus-based regimen for GVHD prophylaxis. Results & conclusion: The findings of the present study suggests that CYP3A5 genotype may impact attainment of initial therapeutic tacrolimus concentrations with oral administration in alloHCT recipients.

View details for DOI 10.2217/pgs-2023-0204

View details for Web of Science ID 001143092600001

View details for PubMedID 38189154